Description: Lava Therapeutics B.V., a biotechnology company, develops proprietary Vγ9Vδ2 T-cell engagers. It develops immune oncology biopharmaceuticals that delivers treatment in combination with immune recruiting and activating functionality. The company was founded in 2016 and is based in Utrecht, the Netherlands.
Home Page: www.lavatherapeutics.com
LVTX Technical Analysis
Yalelaan 60
Utrecht,
3584 CM
Netherlands
Phone:
31 630 00 30 35
Officers
| Name | Title |
|---|---|
| Mr. Stephen Allen Hurly M.B.A., M.Sc. | CEO, Pres & Exec. Director |
| Mr. Peter Ros | VP of Fin. |
| Mr. Fred M. Powell CPA | Chief Financial Officer |
| Dr. Hans van der Vliet M.D., Ph.D. | Chief Scientific Officer |
| Ms. Amy Garabedian J.D. | Gen. Counsel & Corp. Sec. |
| Mr. Wouter van Hunnik | VP & Head of HR |
| Dr. Benjamin Winograd M.D., Ph.D. | Chief Medical Officer |
| Dr. Ton Adang Ph.D. | Chief Devel. Officer |
| Dr. Paul W. H. I. Parren Ph.D. | Exec. VP, Head of R&D and MD |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.4157 |
| Price-to-Book MRQ: | 1.8811 |
| Price-to-Sales TTM: | 5.8096 |
| IPO Date: | 2021-03-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |